R175H and R273H are more prone to aggregation than wild-type (WT) p53, and their pathological aggregation can lead to various cancers. A recent study investigated the dynamic and …

May 25, 2021 · Here, we reported that a new quinolone compound RYL-687 significantly inhibited non-small cell lung cancer (NSCLC) cells which express wild type (wt) p53, in contract to its …

We have shown that targeting the metabolic pathways of EAC cells harboring the R248W mutation provides a therapeutic window compared to WT-p53 cells, as treatment effects were …

Jul 13, 2012 · As published recently in Cancer Cell, p53 impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. I discuss that, while treating tumors …

Mar 28, 2024 · However, when bona fide wild-type (WT) p53 was finally tested, it not only failed to elicit oncogenic transformation of cultured cells—it actually potently suppressed transformation …

Among them, PRIMA-1 is a p53-independent negative regulator that enhances the thermal stability of mutant p53, thereby promoting the refolding of mutant p53 into the p53 wt …

Jan 11, 2023 · Efforts to reactivate wild-type p53 function and inhibit mutant functions have been complicated by the variety of TP53 mutations. Identified from a screen, the NSC59984 …

Expression of exogenous wt-p53 suppresses a variety of leukaemia phenotypes by acting on cell survival, proliferation and/or differentiation. As for tumour gene therapy, the final fate of the …

Aug 8, 2018 · Single residue changes, caused by hot-spot mutations of the TP53 gene in human cancer, transform wild-type (wt) p53 tumor suppressor proteins into potent oncoproteins - with …

Different input signals such as oncogene activation, DNA damage, mitotic impairment or oxidative stress must be assimilated by p53 to initiate the correct transcriptional response promoting …